HER2-mutant NSCLC was a major focus at IASLC WCLC 2026, with trastuzumab deruxtecan and the…
Browsing: biotech analysis
Non-small cell lung cancer was the dominant theme at WCLC 2026, with advances across targeted…
PARP inhibitors were discussed at WCLC 2026 highlights in the context of DNA damage response…
Armored CAR-T cell therapies were featured at WCLC 2026 late-breaking abstracts with early clinical data…
KRAS inhibitors were a highlight at WCLC 2026 oral presentations, with divarasib (G12C) and rilvegostomig…
HER2-directed ADCs were a major focus at WCLC 2026 Seoul, with trastuzumab deruxtecan and the…
SEZ6 was featured at WCLC 2026 Seoul as a novel therapeutic target in small-cell lung…
GenFleet Therapeutics was present at WCLC 2026 through its innovative targeted therapy pipeline for molecularly…
NTRK1/2/3 was discussed at IASLC WCLC 2026 in sessions exploring rare oncogenic drivers and tumour-agnostic…
Astellas Pharma was present at WCLC 2026 abstracts through its oncology research and drug development…